X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA GLENMARK PHARMA AJANTA PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 21.4 14.1 151.7% View Chart
P/BV x 9.2 3.9 234.2% View Chart
Dividend Yield % 0.6 0.3 201.8%  

Financials

 AJANTA PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
GLENMARK PHARMA
Mar-16
AJANTA PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,7201,262 136.3%   
Low Rs1,103672 164.3%   
Sales per share (Unadj.) Rs194.6270.6 71.9%  
Earnings per share (Unadj.) Rs45.224.9 181.8%  
Cash flow per share (Unadj.) Rs50.334.4 146.1%  
Dividends per share (Unadj.) Rs8.002.00 400.0%  
Dividend yield (eoy) %0.60.2 274.0%  
Book value per share (Unadj.) Rs132.0151.3 87.2%  
Shares outstanding (eoy) m88.77282.16 31.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.33.6 203.0%   
Avg P/E ratio x31.238.9 80.3%  
P/CF ratio (eoy) x28.128.1 99.9%  
Price / Book Value ratio x10.76.4 167.4%  
Dividend payout %17.78.0 220.1%   
Avg Mkt Cap Rs m125,299272,778 45.9%   
No. of employees `000NA10.0 0.0%   
Total wages/salary Rs m2,57013,782 18.6%   
Avg. sales/employee Rs ThNM7,614.9-  
Avg. wages/employee Rs ThNM1,374.8-  
Avg. net profit/employee Rs ThNM700.2-  
INCOME DATA
Net Sales Rs m17,27576,340 22.6%  
Other income Rs m166356 46.7%   
Total revenues Rs m17,44276,696 22.7%   
Gross profit Rs m5,80714,172 41.0%  
Depreciation Rs m4512,691 16.7%   
Interest Rs m491,789 2.7%   
Profit before tax Rs m5,47410,048 54.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,4603,028 48.2%   
Profit after tax Rs m4,0147,019 57.2%  
Gross profit margin %33.618.6 181.1%  
Effective tax rate %26.730.1 88.5%   
Net profit margin %23.29.2 252.7%  
BALANCE SHEET DATA
Current assets Rs m7,63959,096 12.9%   
Current liabilities Rs m2,71540,018 6.8%   
Net working cap to sales %28.525.0 114.1%  
Current ratio x2.81.5 190.5%  
Inventory Days Days4375 57.7%  
Debtors Days Days79119 66.0%  
Net fixed assets Rs m6,91439,075 17.7%   
Share capital Rs m177282 62.7%   
"Free" reserves Rs m11,44230,281 37.8%   
Net worth Rs m11,72142,703 27.4%   
Long term debt Rs m14924,873 0.6%   
Total assets Rs m14,814111,026 13.3%  
Interest coverage x112.96.6 1,707.0%   
Debt to equity ratio x00.6 2.2%  
Sales to assets ratio x1.20.7 169.6%   
Return on assets %27.47.9 345.7%  
Return on equity %34.216.4 208.4%  
Return on capital %46.517.5 265.7%  
Exports to sales %55.143.3 127.4%   
Imports to sales %6.07.4 80.8%   
Exports (fob) Rs m9,52733,044 28.8%   
Imports (cif) Rs m1,0385,672 18.3%   
Fx inflow Rs m10,42236,945 28.2%   
Fx outflow Rs m1,67861,066 2.7%   
Net fx Rs m8,744-24,122 -36.2%   
CASH FLOW
From Operations Rs m3,2643,449 94.6%  
From Investments Rs m-2,093-8,802 23.8%  
From Financial Activity Rs m-1,1866,986 -17.0%  
Net Cashflow Rs m-15934 -1.6%  

Share Holding

Indian Promoters % 73.8 48.3 152.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 6.9 22.5%  
FIIs % 7.6 34.4 22.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 10.5 161.9%  
Shareholders   20,968 56,727 37.0%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  DR. REDDYS LAB  GSK PHARMA  

Compare AJANTA PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Infosys Surges 3% on Buyback News(09:30 am)

Majority of Asian stock indices are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.26% while the Hang Seng is up 0.05%.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Aug 17, 2017 11:27 AM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS